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Abstract
Complement plays a major role in inflammation and thrombosis associated with systemic lupus
erythematosus (SLE) and the antiphospholipid syndrome (APS). A cross-sectional retrospective
analysis was performed to evaluate serum complement fixation on platelets and thrombotic incidence
using banked sera and clinical data from patients with SLE (n = 91), SLE with antiphospholipid
antibodies (aPL) or APS (n = 78) and primary aPL (n = 57) or APS (n = 96). In-situ complement
fixation was measured as C1q and C4d deposition on heterologous platelets using an enzyme-linked
immunosorbent assay approach. Platelet activation by patient serum in the fluid phase was assessed
via serotonin release assay. Enhanced in-situ complement fixation was associated with the presence
of IgG aPL and IgG anti-β2 glycoprotein 1 antibodies (P < 0.05) and increased platelet activation
(P < 0.005). Moreover, enhanced complement fixation, especially C4d deposition on heterologous
platelets, was positively associated with arterial thrombotic events in patients with SLE and aPL
(P = 0.039). Sera from patients with aPL possess an enhanced capacity for in-situ complement
fixation on platelets. This capacity may influence arterial thrombosis risk in patients with SLE.
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Complement plays a major role in inflammation and thrombotic complications associated with
systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). APS is an
autoimmune thrombophilic condition associated with the presence of antiphospholipid
antibodies (aPL), but not all patients with aPL have or develop APS.1,2 The risk of thrombosis
is particularly high in patients with SLE and aPL.3 Understanding the pathophysiology of
thrombosis in this setting and developing targeted preventive strategies is thus highly relevant.
In-vivo and in-vitro studies show that aPL activate endothelial cells and platelets and contribute
to thrombosis and tissue injury.4–9 A major antigen recognized by aPL is β2 glycoprotein 1
(β2GP1), a member of the complement control protein superfamily.1 Proposed mechanisms
for the thrombotic potential of anti-β2GP1 antibodies include interference with endogenous
anticoagulation mechanisms by anti-β2GP1 immune complexes, the triggering of signalling
events on cells including endothelial cells, platelets, trophoblasts and leukocytes and
complement activation with an ensuant inflammatory reaction on the vascular and trophoblast
surface.1,10–12
In addition, complement activation has been implicated in thrombotic complications associated
with APS.1,10 In-vivo complement activation is required for aPL-induced foetal loss and
growth retardation.11 Moreover, an increase in complement activation products in the serum
of patients with aPL has been associated with the development of stroke and transient ischemic
events.13 A high frequency of complement fixing aPL has been described in patients with
APS.14 Recently, platelet-associated C4d was reported in 18% of patients with SLE and was
significantly associated with the presence of a lupus anticoagulant and anticardiolipin
antibodies.15
Indeed, platelets have been described as targets of circulating aPL.4 The interaction of aPL
with platelets has been reported to occur by several mechanisms, including direct recognition
of platelet antigens, cross-linking apolipoprotein E R212 and antibody interaction with platelet
FcγRII receptors.4 Depending on antibody isotype, platelet-associated aPL may thus play a
role in the activation of the classical complement pathway, leading to deposition of classical
complement components, including C4d, a stable degradation product of C4b, on the platelet
surface.
The present study was conducted to test the hypothesis that enhanced in-situ classical pathway
complement activation on platelets is associated with thrombotic events in patients with SLE
and/or aPL antibodies. A recently developed in-vitro assay measuring complement fixation on
immobilized heterologous platelets16 was used to evaluate in-situ complement activation by
sera from patients with SLE, SLE with aPL or APS and patients with primary aPL or APS.
The data show an enhanced capacity of sera from patients with aPL to activate complement




A cross-sectional retrospective analysis was performed using banked sera from patients having
SLE, with or without aPL or APS, and patients with primary aPL or APS. The study was
performed in accordance with the guidelines of the Weill Medical College of Cornell
University and Hospital for Special Surgery Institutional Review Boards for the Protection of
Human Subjects and the Helsinki Declaration of 1975, as revised in 1983.
Peerschke et al. Page 2













Patients with SLE met American College of Rheumatology criteria for SLE.17 All patients
with APS had a history of IgG or IgM anticardiolipin antibodies (aCL), anti-β2GP1 IgG or
IgM antibodies and/or positive lupus anticoagulant tests documented on two or more occasions
at least 6 weeks apart and met Sapporo clinical criteria.2 All patients having aPL without APS
met the above laboratory criteria but not Sapporo clinical criteria. SLE patients without aPL
had at least one documented negative test result for a lupus anticoagulant and negative IgG,
IgM and IgA aCL antibodies.
Banked sera and clinical data for patients having SLE with aPL or APS (n = 78) and SLE
patients without aPL (n = 91) were obtained from the Hospital for Special Surgery Autoimmune
Disease Registry. The clinical and laboratory characteristics of these patient populations were
recently described in detail.18
Sera and corresponding clinical and laboratory data for patients with primary aPL or APS (n
= 153) were obtained from the national Antiphospholipid Syndrome Collaborative Registry
(APSCORE).
Immunoassays
aPL levels for both SLE patients and patients in the APSCORE registry were determined on
the same serum samples used for complement activation. For the SLE patient cohort, IgG and
IgM APhL levels were determined by a commercial immunoassay kit (Louisville APhL
Diagnostics, Seabrook, Texas, USA) using a proprietary phospholipid mixture and β2GP1 as
substrate coated on polystyrene platelets. APhL levels have been shown to correlate with aCL
levels and may be more specific for APS.19,20 Results are expressed as standard GPL and
MPL units.21 IgG and IgM anti-β2GP1 levels were assayed using a commercial immunoassay
kit (Inova Diagnostics, San Diego, California, USA) with levels reported as standard IgG
(SGU) or IgM (SMU) units.
For aPL and APS patients enrolled in the APSCORE registry, aCL and β2GP1 antibody levels
were determined centrally by the registry. aCL levels were determined using a kit from
Louisville aPL Diagnostics. β2GP1 antibody levels were measured with an immunoassay kit
from Inova Diagnostics.
Positive levels for all aPL antibodies (APhL, aCL and anti-β2GP1 IgG and IgM) were defined
as >20 units, following normalization to appropriate assay standards supplied by the respective
manufacturers.
Complement activation on heterologous platelets
A solid phase assay was used to measure the capacity of patient sera to activate the classical
complement pathway on immobilized heterologous platelets. Platelets were obtained from
healthy volunteers as previously described.16 Briefly, blood was collected into 3.2% sodium
citrate (9:1 blood: anticoagulant ratio), after obtaining informed consent. Platelet rich plasma
was prepared by centrifugation at 280 g for 8 min. Platelets were washed by centrifugation
(1000 g, 15 min) in the presence of 10 mM ethylenediaminetetra acetic acid (EDTA). The
resulting cell pellet was resuspended in 0.01 M HEPES (N-2 hydroxyethyl piperazine ethane
sulfonic acid)-buffered modified Tyrode’s solution (HBMT) containing 1 mM MgCl2, 1 mM
CaCl2 and 2 mg/mL bovine serum albumin (BSA) (fatty acid free; Sigma-Aldrich, St Louis,
Missouri, USA). No attempt was made to fully prevent platelet activation during the washing
procedure. Washed platelets were immobilized on microtitre plate wells using poly-L lysine,
as described.16 Adherent platelets were fixed with 0.5% glutaraldehyde in 0.01 M phosphate
buffered 0.14 M NaCl (PBS), pH 7.5. Microtitre wells were blocked with glycine 1% BSA and
washed with HBMT.22 Immobilized platelets were exposed (60 min, 37 °C) to patient sera or
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sera from healthy volunteers (n = 50). All serum samples were diluted (1/10) in HBMT
containing 1 mM CaCl2, 1 mM MgCl2 and 50 µM D-phenylalanyl-L-prolyl-L arginine
chloromethyl ketone (PPACK) (Calbiochem, San Diego, California, USA) to prevent
thrombin-mediated complement activation.23 Complement fixation was assessed by
examining the deposition of classical pathway complement components C1q and C4d using
commercially available monoclonal antibodies (Qui-del Corp., Santa Clara, California, USA;
final concentration of 10 µg/mL). Primary antibody binding was detected with an alkaline
phosphatase-conjugated goat antimouse secondary antibody F(ab’)2 fragment and para-
nitrophenyl phosphate (p-NPP) substrate, both from Sigma-Aldrich. Substrate conversion was
measured spectrophotometrically at 405 nm. Nonimmune mouse IgG1κ (MOPC21, Sigma-
Aldrich; 10 µg/mL) served as a negative control antibody. Assay reactivity noted in the
presence of nonimmune mouse IgG was subtracted from all experimental results. Immobilized
platelets were screened for intrinsic C1q or C4d reactivity by incubation with HBMT instead
of serum and no reactivity was detected.
Assay results were normalized to an internal assay standard to facilitate interassay
comparisons. This standard was prepared by pooling serum from 25 healthy donors and was
stored in aliquots at −80 °C.
Reference ranges for the assay were established using serum samples from 50 healthy
volunteers, who had not taken any medication for at least 10 days. Volunteers ranged in age
from 25 to 67 years. Equal numbers of male and female volunteers were studied.
Platelet activation
To evaluate platelet activation in the fluid phase, a serotonin release assay (SRA) was
performed as previously described.24 Briefly, 14C-serotonin (33 nCi/mL) (Amersham
Bioscience, Piscataway, New Jersy, USA) was added to platelet-rich plasma, prepared by
centrifugation of anticoagulated (3.2% sodium citrate) whole blood at 280 g for 8 min. After
incubation at 37 °C for 30 min, samples were centrifuged in the presence of 10 mM EDTA
(1000 g, 20 min), and platelets were resuspended in HBMT to a count between 200 and 300
K/µL. 14C-serotonin-labeled platelets were subsequently exposed to healthy donor or patient
sera, diluted 1:10 in HBMT, to mimic conditions used in complement fixation studies.
Following incubation at 37 °C for 60 min, samples were fixed with ice-cold 1% formalin
(Sigma-Aldrich) and centrifuged (12,000 g, 5 min). The platelet-free supernatant was evaluated
for released 14C-serotonin using liquid scintillation counting.
Statistical evaluations
Continuous data were evaluated using the unpaired student’s t-test for parametric data and the
Mann-Whitney U-test for nonparametric data. Nominal data were evaluated by chi-squared or
Fisher’s exact test. All analyses were two-tailed and P < 0.05 were considered significant.
Results
Patient demographics
A total of 169 serum samples from patients with SLE were analysed. Patient demographics
relevant to the present study are summarized in Table 1. Ninety-one patients were aPL negative
and 78 were aPL positive. aPL refers collectively to aPhL, aCL and β2GP1 antibodies. APhL
IgG and IgM levels were positive, respectively, in 87 and 64% of SLE patients with aPL/APS.
Levels of anti-β2GP1 IgG and IgM were positive in 53 and 46% of these patients, respectively.
The presence or absence of a lupus anticoagulant was not be assessed at the time of study, as
only serum samples, and not plasma samples, were available for analyses. Of the SLE patients
whose sera were aPL positive, 27 patients had aPL without APS and 51 had APS by Sapporo
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criteria.2 In the latter group, 41 patients experienced at least one thrombosis (32 arterial and
17 venous) and 23 patients experienced at least one pregnancy morbidity. aPL IgG levels
trended towards higher levels in patients with SLE and APS (P = 0.057).
In addition, a total of 153 banked sera from patients with primary aPL (96 without APS, 57
with APS) were analysed. Relevant patient demographics are summarized in Table 2. At the
time of study, 88 and 45% of patients with APS exhibited positive serum titres for cardiolipin
IgG and IgM, respectively. In addition, 73 and 56% of these patients were positive for serum
IgG and IgM antibodies against β2GP1. Similarly, serum levels for anticardiolipin IgG and
IgM were positive in 51 and 37% of patients with aPL without APS, respectively. Serum levels
for β2GP1 IgG and IgM were positive in 33 and 35% of these patients, respectively. Serum
levels for anticardiolipin and anti-β2GP1 IgG were higher in aPL patients with APS than in
aPL patients without APS, whereas the incidence of lupus anticoagulant positivity was similar.
Of the 96 patients with aPL and APS, 74 experienced at least one thrombosis (44 arterial and
36 venous) and 37 patients experienced at least one pregnancy morbidity.
Complement fixation
Results for in-situ complement fixation by sera from patients with SLE and healthy controls
are shown in Figure 1. Deposition of classical pathway complement components, C1q (panel
A) and C4d (panel B), is expressed as a ratio relative to an internal assay standard. Mean and
median values for C1q and C4d deposition are illustrated in Figure 2. As described previously,
16 C1q and C4d deposition occurred on immobilized platelets following exposure to normal
human serum. The extent of complement deposition was previously found to be similar using
autologous and heterologous serum from untransfused donors, suggesting a lack of effect from
or sensitivity to ABO or HLA mismatch.16 In addition, previous studies showed similar levels
of complement activation measured on platelets exposed to serum or plasma.16
In the present study, the reference interval for normalized C1q and C4d deposition (ratio) on
heterologous platelets determined using sera from healthy volunteers (n = 50) was 1.0 ± 0.30
and 1.13 ± 0.60, respectively. A small but significant increase in C1q deposition was noted
using sera from patients with SLE without aPL (1.21 ± 0.47; P = 0.006). However, a marked
decline in C4d deposition was seen in this population (0.61 ± 0.32; P < 0.0001) likely due to
overall decreased serum complement levels (Table 1) relative to published reference ranges.
25 Decreased serum complement is often seen in the setting of SLE and related to consumption
and/or genetics.26,27 In contrast, aPL positive sera from patients with SLE showed
significantly increased C1q deposition (1.85 ± 0.81) (Figure 1A) compared with sera from
healthy volunteers (P < 0.0001). C4d deposition was similar (1.16 ± 0.85) to that found with
serum from healthy volunteers but significantly increased (P < 0.0001) relative to aPL negative
sera from patients with SLE (Figure 1B). There was no correlation between the magnitude of
C1q or C4d deposition (ratio) and aPL levels in patients with SLE (data not shown).
Sera from patients with primary aPL or APS also showed increased C1q and C4d deposition
compared with normal serum (Figure 2). However, relative to results obtained with normal
serum only increases in C1q deposition were statistically significant (aPL only, P = 0.03; aPL
with APS, P = 0.06). There was a trend towards increased C4d deposition using sera from
patients with aPL only (P = 0.09) or aPL with APS (P = 0.10), but these did not reach statistical
significance.
To further evaluate the relationship between complement fixation, aPL level and thrombosis,
patient sera were designated as either ‘complement positive’ (C+) or ‘complement negative’ (C
−). Complement positivity was defined as a ratio greater than 2.0 for serum C1q or C4d
deposition relative to control serum. This cutoff represents in-situ C1q or C4d deposition
exceeding two standard deviations above the normal reference mean (>95th percentile). As
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shown in Table 3, complement positive sera showed higher IgG APhL and anti-β2GP1 levels,
regardless of the patient population. Notably, only three of 88 aPL negative patients with SLE
were complement positive by this definition.
In SLE patients with aPL, complement positivity was significantly associated with a history
of arterial thrombosis (Table 4). Reported arterial events were heterogeneous and included
predominantly (68%) cerebrovascular accidents. No association was noted with history of
venous thrombosis, foetal loss or overall incidence of thrombosis in this population.
Complement positivity conferred a 2.74 greater odds for arterial thrombosis in SLE patients
with aPL (P = 0.03, 95% CI = 1.08–6.94). After adjusting for APhL or anti-β2GP1 level in a
multivariate analysis, the odds ratio decreased to 2.04 (95% CI = 0.76–5.50) and 2.27 (95%
CI = 0.86–6.0) (not statistically significant), suggesting possible confounding effects of aPL
level on complement activation. Interestingly, no association emerged between complement
fixation and thrombosis in patients with primary aPL.
To further evaluate the relationship between aPL level, complement fixation and arterial
thrombosis in SLE patients, the positive predictive value (PPV) for arterial thrombosis was
compared for a positive APhL level alone and the combination of a positive APhL level with
a positive complement fixation ratio ≥2.0. A positive APhL level alone had a PPV of 41% for
arterial thrombosis and a negative predictive value (NPV) of 61%. In the presence of a
simultaneously positive complement fixation test, the PPV increased to 54%, with a NPV of
68%. If only C4d deposition on heterologous platelets was used as a measure of complement
fixation, the number of false positive test results decreased and the PPV increased to 70% (NPV
69%). Moreover, if the positive cutoff for C4d deposition was raised to a ratio greater than 2.5,
the PPV for arterial thrombosis for the combination of a positive APhL level with a positive
complement fixation increased to 83% (NPV 64%).
Platelet activation
Additional studies compared the ability of a subgroup of sera (selected based upon availability),
designated complement positive or negative, to activate heterologous platelets in suspension,
using a 14C serotonin release assay. The data are summarized in Table 5. Statistically significant
increases in 14C-serotonin secretion were observed following platelet exposure to complement
positive sera, regardless of the patient population.
Discussion
Results from the present study show that sera from patients with aPL exhibit an enhanced
capacity to activate the classical pathway of complement, defined by C1q and/or C4d
deposition on heterologous platelets. In aPL patients with underlying SLE, deposition of C1q
and especially C4d, exceeding twice the level observed with normal serum, was associated
with an increased incidence of arterial thrombosis. Despite enhanced classical pathway
complement activation by sera from patients with primary aPL, a similar association with
arterial thrombosis was not observed. A significant association, however, was noted between
the presence of aPL IgG and positive complement fixation on heterologous platelets in all
patients, although the correlation between the magnitude of aPL levels and the extent of
complement deposition was poor, likely reflecting heterogeneity in the complement fixing
ability of the autoantibodies present.
At the time of inclusion, none of the patients were receiving any form of heparin therapy. This
is relevant because heparin can inhibit complement activation.28 However, some patients in
both the SLE and APSCORE registries were receiving anticoagulation therapy with warfarin.
In the APSCORE cohort, 4/47 aPL patients were receiving warfarin, compared with 59/96
patients with APS. In the SLE cohort, 3/91 aPL negative patients and 28/78 aPL positive
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patients were treated with warfarin. Although vitamin K antagonism is not expected to directly
impact the complement system, thrombin generation may indirectly enhance complement
activation.23 For this reason, in-situ complement activation on immobilized platelets was
assayed in the presence of a direct thrombin inhibitor (PPACK).
The association between serum complement fixation and arterial thrombosis in patients with
SLE and aPL, but not primary aPL, may suggest that other SLE-related factors are
mechanistically important for arterial thrombosis in the setting of aPL-mediated complement
activation. Alternatively, or in addition, the variance in C1q and C4d deposition observed with
sera from patients with primary aPL was greater than that noted with sera from normal controls
or patients with SLE. This may reflect preanalytical variables associated with serum
preparation and storage that could affect complement activation29 and may have contributed
to the apparent lack of association between complement positivity and thrombotic events in
patients with primary aPL.
The following mechanism for the interaction between aPL, complement activation and arterial
thrombosis may be plausible. Circulating aPL auto-antibodies bind to the platelet surface,
creating an immune complex that, depending on antibody isotype, is recognized by
complement (i.e., C1q). In-situ complement activation subsequently occurs on the platelet
surface, as evidenced by C4d deposition. Platelet activation by complement,30 as observed in
vitro using the serotonin release assay, and the generation of complement-derived
inflammatory mediators 31 may promote arterial thrombosis. In the setting of SLE, vascular
injury may create an environment that predisposes to platelet accumulation and subsequent in-
situ complement activation.
The complement system plays an important role in the pathogenesis of SLE. Complement
deficiencies in the classical pathway (C1q, C4 and C2) predispose to the development of
autoimmunity by a variety of mechanisms including impaired clearance of immune complexes
and apoptotic cells, as well as aberrant tolerance induction and changes in cytokine regulation.
26,27 During SLE flares, the complement system is activated, giving rise to partial deficiency
or dysfunction due to consumption.27 Complement activation takes part in inflammatory
reactions that give rise to tissue and organ damage.26 Because the extent of complement
consumption in SLE patients likely impacts measurable complement deposition on platelets
in the current assay, a limitation of our study is the inability to assay C1q levels and C4 levels
in all serum samples due to limited sample volume. Thus, it was not possible to normalize
complement deposition to serum complement levels. Indeed, C4d deposition was lowest in
samples with lowest C4 levels. This may have increased false negative results.
Another significant limitation of the present study is the inability to correlate complement
activation with lupus anticoagulant information. Determination of lupus anticoagulant status
is indeed important for an APS series. Although these data were available for most samples in
the APSCORE cohort (Table 2), platelet–poor plasma samples were unavailable for analysis
in the SLE cohort, and thus, concurrent lupus anticoagulant measurements could not be made.
It should be noted, however, that various APSCORE and patients with SLE were on warfarin
therapy, which may interfere with lupus anticoagulant measurement. Thus, even if lupus
anticoagulant data were available for all patients, the percentage of true positive patients would
be overestimated.
The role of complement in APS is under intense investigation. Multiple pathogenic
mechanisms have been suggested.32 Exposure of human endothelial cells to aPL has been
shown to result in tissue factor production and upregulation of adhesion molecules.33 Although
the cause of tissue injury in APS is likely to be multifactorial,32,34 a substantial body of
evidence shows that complement activation is a requirement for pregnancy complications and
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thrombosis.12 Potentially, aPL-mediated complement fixation contributes to arterial
thrombosis via production of inflammatory mediators: C3a responsible for leukocyte
recruitment35 and C5a stimulating endothelial cell production of tissue factor.36 The presence
of receptors for anaphylatoxins has also been described in human coronary plaques, suggesting
that they may play a role in plaque formation/progression.37
In patients with SLE, cross-sectional and prospective cohort studies show a predictive role of
aPL for future vascular events.38,39 However, patients with SLE are at significantly increased
risk of premature atherosclerosis and/or thrombosis,40,41 regardless of aPL status, and a
significant aPL profile does not appear to be predictive of thrombosis in individual patients
with SLE.42 Moreover, a positive aPL level does not predict the location of thrombotic events
(arterial, venous, pregnancy complications). Results from the present study suggest that the
ability of sera with positive aPL levels to substantially activate complement on platelets may
be associated with arterial thrombosis in patients with SLE, particularly when the complement
fixation assay is made more stringent by using C4d generation as the endpoint. This may
suggest that observed C1q deposition on heterologous platelets reflects the presence of
complement fixing antibodies on platelets, whereas the in-situ generation of C4d is indicative
of the activation of the classical complement system and its inflammatory sequelae. The current
study did not have sufficient power to distinguish between specific arterial thrombotic events,
such as stroke and myocardial infarction. The majority of patients with arterial thrombotic
events (22 of 32) had a history of cerebrovascular accidents, and a history of myocardial
infarction was reported for two patients. Other reported arterial thrombotic events included
digital, splenic and adrenal infarcts.
In summary, the present study provides further insight into potential pathophysiologic
mechanisms associated with thrombotic complications in SLE patients with aPL. Prospective
studies are warranted to determine whether direct measurement of C1q and C4d deposition on
circulating platelets, or enhanced complement fixation on heterologous and/or homologous
platelets in situ, may be useful in predicting arterial thrombosis risk in patients with SLE. This
information could contribute to more targeted therapeutic interventions in patients having SLE
with aPL.
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Complement fixation on heterologous platelets by serum from healthy volunteers (normal, n
= 50), patients with SLE without aPL (n = 91) and patients with SLE and aPL or APS (n = 78).
Classical pathway C1q (Panel A) and C4d (Panel B) deposition are shown. Each data point
represents results for a single patient. The horizontal line indicates mean complement
component deposition for the group. Complement deposition is expressed as a ratio relative to
a normal human serum pool (NHS), used as an internal assay standard, as described in Methods.
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Comparison of complement fixation on heterologous platelets by serum samples from patients
with primary aPL, SLE with aPL. The data depict mean (horizontal line), median (box) and
standard deviation for C1q (Panel A) and C4d (Panel B) deposition for serum samples from
patients with primary aPL with APS (APS, n = 96), primary aPL only (aPL, n = 57), SLE with
aPL or APS (SLE +aPL/APS, n = 78) and SLE without aPL (SLE, n = 91). Complement fixation
by serum from healthy volunteers (n = 50, normal) is shown for reference. Complement
deposition is expressed as a ratio relative to an internal normal human serum standard, as
described in Methods. The asterix (*) denotes statistically significant differences in
complement deposition compared with normal (P < 0.05).
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Table 2




n = 96 P value
Demographics
  Age, years 40 ± 13 40 ± 11 0.535
  Female, n (%) 60 (88%) 68 (80%) 0.213
  White race, n (%) 58 (85%) 64 (75%) 0.197
Laboratory characteristics
  Anticardiolipin
   IgG, GPL units 57 ± 62 84 ± 77 0.017
   IgM, MPL units 38 ± 69 21 ± 39 0.120
  Anti-β2GP1
   IgG, SG units 47 ± 67 84 ± 126 0.006
   IgM, SM units 53 ± 74 47 ± 109 0.472
  Lupus anticoagulant
   Positive, n+/n (%) 32/49 (65%) 71/84 (85%) 0.272
  Thrombotic complications
   Arterial, n (%) 0 44 (46%)
   Venous 0 0 36 (38%)
   Pregnancy 0 0 37 (39%)
Values are presented as mean ± SD.
n+/n, number of patients with finding/number of patients with available data.
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Table 5
Comparison of platelet activation by complement positive or complement negative sera from patients with aPL
14C-Serotonin release (%)
Patients C+ C− P value
SLE with aPL 55 ±11 (n = 12) 28 ± 15 (n = 5) 0.002
Primary aPL 70 ± 10 (n = 7) 44 ± 10 (n = 4) 0.004
Normal NA 14 ± 8 (n = 5)
Platelet activation was assessed by 14C-serotonin release assay. Results are expressed as mean ± SD.
Patient sera were selected based on sample availability.
Sera were defined as complement positive (C+)if the levels of C1q and/or C4d deposition exceeded twice that obtained with an internal assay standard,
as described in Methods.
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